What is the mechanism of action of adagrasib?

Adagrasib is a targeted therapy drug that is a KRAS G12C inhibitor. It is designed to treat advanced or metastatic non-small cell lung cancer (NSCLC) with the KRAS G12C mutation and other solid tumors with the same mutation. The mechanism of action of adagrasib is closely related to its targeting properties against the KRAS G12C mutant.

KRAS G12Cis a mutated form of theRAS family and is one of the most common oncogenic mutations in many cancers. This mutation results in an abnormally active RAS signaling pathway that promotes cancer cell growth, proliferation, and survival. Adagarasib is unique in its ability to specifically bind and inhibit KRAS G12C mutants.

The mechanism of action of adagrasib is as follows:

1.Selective binding: Adagrasib has a highly selective binding effect with KRAS G12C mutant, forming a stable drug - target protein complex.

2.InhibitionKRASActivity: Once bound to the KRAS G12C mutant, adagrasib will interfere with its normal cell signaling function, thereby inhibiting the growth and proliferation of cancer cells.

3.Block downstream signaling: KRAS G12Cmutant participates in multiple downstream signaling pathways and promotes the growth and survival of cancer cells. The effect of adagrasib results in the blocking of these signaling pathways, thereby hindering the proliferation and metastasis of cancer cells.

4.Induction of apoptosis: The effects of adagrasib may induce apoptosis (programmed cell death) in cancer cells, thereby reducing tumor size and burden.

Overall, adagrasib interferes with the growth signaling of cancer cells by specifically inhibiting the activity of the KRAS G12C mutant, thereby inhibiting tumor growth and spread. This makes it a new type of targeted therapy drug, providing new treatment options for tumor patients with KRAS G12C mutations and bringing new hope to the field of cancer treatment.